RESUMO
Objective To study clinical effects of the fexofenadine hydrochloride Tablets and BCG-PSN in the treatment of chronic urticaria. Methods 122 patients with chronic urticaria treated in Yiwu skin disease hospital from January 2016 to March 2017 were selected and randomly divided into the control group and the experimental group, 61 patients for each group. The control group was given Fexofenadine Hydrochloride Tablets treatment, the experimental group was given BCG-PSN on the basic treatment of the control group. The patients in the experimental group and the control group were treated for 3 months. The treatment effect and adverse reactions were compared between two groups. Results After the corresponding treatment, the number of invalid cases in the experimental group was 10. In the control group, 21 cases were ineffective. The effective rate of the experimental group was 63.93%, which was significantly higher than 32.97% of the control group with statistical significance (P<0.05). There were no obvious adverse reactions in the two groups, and there was no significant difference in the incidence of adverse reactions. After treatment, the integral score of the experimental group was (3.20±0.42), significantly lower than that of the control group (3.98±0.37), with statistical significance (P<0.05). Conclusion fexofenadine hydrochloride Tablets combined with BCG-PSN for the treatment of chronic urticaria could significantly improve clinical symptoms of patients with good efficacy, high safety and clinical application significance.
RESUMO
Objective To study clinical effects of the fexofenadine hydrochloride Tablets and BCG-PSN in the treatment of chronic urticaria. Methods 122 patients with chronic urticaria treated in Yiwu skin disease hospital from January 2016 to March 2017 were selected and randomly divided into the control group and the experimental group, 61 patients for each group. The control group was given Fexofenadine Hydrochloride Tablets treatment, the experimental group was given BCG-PSN on the basic treatment of the control group. The patients in the experimental group and the control group were treated for 3 months. The treatment effect and adverse reactions were compared between two groups. Results After the corresponding treatment, the number of invalid cases in the experimental group was 10. In the control group, 21 cases were ineffective. The effective rate of the experimental group was 63.93%, which was significantly higher than 32.97% of the control group with statistical significance (P<0.05). There were no obvious adverse reactions in the two groups, and there was no significant difference in the incidence of adverse reactions. After treatment, the integral score of the experimental group was (3.20±0.42), significantly lower than that of the control group (3.98±0.37), with statistical significance (P<0.05). Conclusion fexofenadine hydrochloride Tablets combined with BCG-PSN for the treatment of chronic urticaria could significantly improve clinical symptoms of patients with good efficacy, high safety and clinical application significance.